Nicoletta Loggia, Ph.D., R.Ph
Nicoletta Loggia, Ph.D., R.Ph, has more than 20 years of leadership experience delivering on all facets of technical operations within the biopharmaceutical industry. Dr. Loggia expertise spans the development and commercialization of biologics, small molecules, and cell and gene therapies. Currently, she is the Chief Technical Officer for Orchard Therapeutics where she is responsible for for CMC process and analytical development, manufacturing, supply chain, distribution, and global quality. Before Orchard, Dr. Loggia served as Global Head of Cell & Gene Therapies at Novartis, where she led multidisciplinary international teams responsible for the end-to-end technical development, manufacturing and project management of several gene and cell therapies, including lentivirus, adeno-associated virus (AAV), stem and CAR-T cell processes, from concept to commercialization. She oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical research and development. Dr. Loggia obtained her Ph.D. in pharmaceutical technologies from the University of Pavia in Italy. She is also a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.